Lly stock forecast outlook strengthened after EU

LLY stock forecast outlook strengthened after EU regulatory approval for tirzepatide. Revenue forecasts adjusted upwards to $50B by 2026, marking one of the fastest growth trajectories in pharma history. The lawsuits filed against Novo allege that the company failed to adequately notify patients and doctors about the serious adverse effects. These range from severe gastrointestinal injuries such as gastroparesis and bowel obstruction to vision-related issues like optic nerve damage. Regarding cardiology, I have highlighted beginning in 2024 a new class of medications, the Lp(a) inhibitors. Lp(a) is an independent risk factor for cardiovascular disease, and it is estimated that 20% of the global population has a level above 50 mg/dL . In the U.S., about 64 million Americans have a high Lp(a) and that 19 million have ASCVD (atherosclerotic cardiovascular disease). Despite the prevalence, testing is rarely done, primarily due to the lack of a pharmacotherapy. However, with several promising therapies now in development (see below), the guideline landscape is changing. The AHA, the ACC, the American Association of Clinical Endocrinology, and the American College of Endocrinology suggest that adults with a family or personal history of premature ASCVD would benefit from Lp(a) testing. However, the latest NLA scientific statement (published in early 2024), the EAS, and the Canadian Cardiovascular Society recommend measuring Lp(a) levels at least once in all adults to refine ASCVD risk. The NLA additionally recommends Lp(a) testing in pediatric patients (< 18 years of age) with suspected or confirmed familial hypercholesterolemia, a family history of premature ASCVD, an unknown cause of ischemic stroke, and/or a parent or sibling with elevated Lp(a) levels . This week’s LLY stock forecast reflects elevated call option activity, suggesting traders are positioning for near-term upside ahead of clinical trial readouts. Implied volatility sits at 24%, offering tactical options plays.